AstraZeneca to take $140M hit for another R&D failure

Embattled AstraZeneca just can't catch a break. The pharma giant ($AZN) scrapped its development plans for the rheumatoid arthritis treatment fostamatinib, planning to take a $140 million write-off on the investment. It's just the latest in a series of development failures for AstraZeneca, which needs new revenue to make up for multibillion-dollar patent losses. Report